login
facebook
google
instagram
linkdin
twitter
youtube

Pancreatic Cancer RibbonSource: Mayo Clinic

Only 1 in 5 U.S. pancreatic cancer patients receive a widely available, inexpensive blood test at diagnosis that can help predict whether they are likely to have a better or worse outcome than average, a Mayo Clinic study shows. People who test positive for elevated levels of a particular tumor marker tend to do worse than others, but if they are candidates for surgery and have chemotherapy before their operations, this personalized treatment sequence eliminates the elevated biomarker’s negative effect, researchers found.

The findings were presented at the Western Surgical Association annual meeting from Nov. 7­-10, 2015 in Napa Valley, California.

“This is another argument for giving chemotherapy before surgery in all pancreatic cancer patients and ending the old practice of surgery followed by chemo,” says senior author Mark Truty, M.D., a gastrointestinal surgical oncologist at Mayo Clinic in Rochester, Minn. “The study answers an important clinical question and applies to every pancreatic cancer patient being considered for surgery.”

The Mayo study, which used the National Cancer Data Base, is the first on the subject based on national data and is the largest of its kind, Dr. Truty says.

Researchers analyzed outcomes for 97,000 patients. The tumor marker whose impact they studied is known as CA 19-9. It is associated with several cancers, including pancreatic cancer, and can be measured in the blood of most people: 10 percent do not produce it. Pancreatic cancer patients who didn’t secrete CA 19­-9 were also studied.

Pancreatic cancer patients whose blood showed higher­-than-­normal CA 19­-9 levels tended to have worse outcomes than others at the same stage of cancer, the study found. Surprisingly, the elevated tumor marker’s negative effect on survival was most pronounced in patients diagnosed at an early stage, the researchers wrote.

“When we looked at how these patients did after surgical removal of their cancers, the only treatment sequence that completely eliminated the increased risk posed by CA 19-­9 elevation was chemotherapy followed by surgical removal of the tumor,” Dr. Truty says.

Another key finding was that only 19 percent of pancreatic cancer patients nationally have their CA 19-­9 checked at diagnosis, far fewer than anticipated, he says. The CA 19­-9 blood test has been standard for pancreatic cancer patients at Mayo Clinic for years.

Failing to test for and address elevated CA 19-­9 means that many patients with above­-normal levels may undergo significant surgeries that may not be as beneficial long term as anticipated, Dr. Truty says.

About 50,000 people are diagnosed with pancreatic cancer each year in the U.S. Historically, only about 7 percent of pancreatic cancer patients have lived at least five years after diagnosis. But advances such as the CA 19-­9 test and improved chemotherapy, radiation and surgical techniques are improving survival odds for many patients, Dr. Truty says.

“Our conclusion is that every patient should have a CA 19-­9 test at diagnosis. This is a simple, cheap and widely available test that allows personalization of pancreatic cancer treatment,” Dr. Truty says, noting that the test costs about $170 ­­ pennies on the dollar relative to the overall cost of a patient’s cancer care. “Further, patients with any elevation of CA 19­-9 should be considered for preoperative chemotherapy to eliminate this risk.”

Mayo Clinic. (2015, November 3). Only one in five U.S. pancreatic cancer patients get this key blood test at diagnosis. ScienceDaily. Retrieved November 3, 2015 from www.sciencedaily.com/releases/2015/11/151103112912.htm
 
 

Edna Dimataga-Fernandez on EmailEdna Dimataga-Fernandez on FacebookEdna Dimataga-Fernandez on GoogleEdna Dimataga-Fernandez on InstagramEdna Dimataga-Fernandez on LinkedinEdna Dimataga-Fernandez on TwitterEdna Dimataga-Fernandez on Youtube
Edna Dimataga-Fernandez
Edna Dimataga-Fernandez founded The Wellness Institute in 2013. The company utilizes a holistic model of wellness consulting focusing on the 6 dimensions of organizational well-being: physical, mental, emotional, social, spiritual & financial health. The Wellness Institute provides holistic health assessments, corporate well-being workshops & wellness consultations with holistic health practitioners. Wellness-Spring, the company’s holistic health store, sells organic & non-toxic health & beauty products. A portion of the proceeds is donated back to causes that support women, children, health, wellness & education. She has worked & consulted for companies in the insurance & financial services industry, the medical & behavioral health field and the non-profit sector. Edna holds a B.A. in Economics from UCLA and an MBA from Keller Graduate School of Management. She is a Past President (2010-11) of the National Association of Insurance & Financial Advisors - Los Angeles Chapter and is an approved Continuing Education Provider for the California Department of Insurance.